Log in to search using one of your social media accounts:

 

With FDA approval in sight, why Aerie's keen on global strategy too
With U.S. Food and Drug Administration approval potentially just around the corner, Aerie Pharmaceuticals (Nasdaq: AERI) has its sights set on global strategy as well. Aerie – which is developing a pipeline of treatments for glaucoma and other eye diseases and is beefing up its research and development team locally – is also well on its way pursuing regulatory approval in both Europe and Japan moving forward. "The company’s success to date, both clinical ly and financially, is what is allowing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 22, 2017 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

With FDA approval in sight, why Aerie's keen on global strategy too
With U.S. Food and Drug Administration approval potentially just around the corner, Aerie Pharmaceuticals (Nasdaq: AERI) has its sights set on global strategy as well. Aerie – which is developing a pipeline of treatments for glaucoma and other eye diseases and is beefing up its research and development team locally – is also well on its way pursuing regulatory approval in both Europe and Japan moving forward. "The company’s success to date, both clinical ly and financially, is what is allowing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2017 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Hiding in plain sight
A tiny implant promises to simplify how glaucoma drugs are administered, making life easier for aging patients. (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - November 21, 2017 Category: Universities & Medical Training Authors: Paula Joyce Source Type: news

Choose DMEK Over DSEK After Glaucoma Surgery Choose DMEK Over DSEK After Glaucoma Surgery
Descemet membrane endothelial keratoplasty provides better outcomes than Descemet-stripping in patients requiring cornea transplant who have already had glaucoma surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Staying Active May Lower Odds for Glaucoma
Title: Staying Active May Lower Odds for GlaucomaCategory: Health NewsCreated: 11/15/2017 12:00:00 AMLast Editorial Review: 11/16/2017 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - November 16, 2017 Category: Opthalmology Source Type: news

Staying Active May Lower Odds for Glaucoma
For each 10-minute increase in moderate-to-vigorous physical activity a week, the risk of glaucoma fell by 25 percent, according to the study. (Source: WebMD Health)
Source: WebMD Health - November 15, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Exercise may protect you from glaucoma
The results of a new study show that people who engage in moderate- to vigorous-intensity exercise have a 73 percent lower risk of developing glaucoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 15, 2017 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Staying Active May Lower Odds for Glaucoma
WEDNESDAY, Nov. 15, 2017 -- You probably know that exercise benefits your heart and waistline. But how about your vision? Researchers at the University of California, Los Angeles analyzed long-term data on American adults, and found that the most... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 15, 2017 Category: General Medicine Source Type: news

HRT may protect against glaucoma
New research presented at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology, reports that oestrogen therapy is associated with a lower risk of eye disease.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 14, 2017 Category: Endocrinology Source Type: news

UC study says exercise could cut glaucoma risk by 73%
A study by the University of California, Los Angeles, has found evidence of a correlation between physical activity and lower rates of the eye disease, particularly among people who work out intensely. (Source: the Mail online | Health)
Source: the Mail online | Health - November 13, 2017 Category: Consumer Health News Source Type: news

Coordination of gaze behavior and foot placement during walking in persons with glaucoma - Miller AB, Lajoie K, Strath RA, Neima DR, Marigold DS.
PURPOSE: Vision normally provides environmental information necessary to direct the foot to safe locations during walking. Peripheral visual field loss limits what a person can see, and may alter how a person visually samples the environment. Here we teste... (Source: SafetyLit)
Source: SafetyLit - November 13, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Two thirds of eye units restricting access to cataract surgery
Commissioners are ignoring NICE guidance, says Royal College of Ophthalmologists Related items fromOnMedica Eye problems Hopes for early warning glaucoma detector STPs can help CCGs deliver eye care at scale Ongoing concerns that cataract surgery being cut to save cash (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 10, 2017 Category: UK Health Source Type: news

People at a low risk of developing glaucoma can avoid unnecessary referral
NICE ’s updated guideline on glaucoma will mean fewer people need to be referred for further specialist investigation and possible treatment. (Source: NHS Networks)
Source: NHS Networks - November 9, 2017 Category: UK Health Source Type: news

Glaukos shares fall despite Q3 beat
Shares in Glaukos (NYSE:GKOS) fell today even though the ophthalmic medical device maker topped expectations on Wall Street with its third quarter results. The San Clemente, Calif.-based company posted profits of $1.3 million on sales of $40.4 million for the 3 months ended Sept.30, for bottom-line growth of 8.3% on sales growth of 36.5% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were 4¢, ahead of consensus on The Street, where analysts were looking for sales of $39.1 million. “As the pioneer of micro-invasive glaucoma surgery, Glaukos continued i...
Source: Mass Device - November 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Optical/Ophthalmic Surgical Wall Street Beat Glaukos Source Type: news

Minnesota Cup winner with eye device raises $1.4M
The startup has developed a tiny implant that aims to treat glaucoma. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 8, 2017 Category: American Health Authors: Katharine Grayson Source Type: news

FDA OKs Vyzulta for Glaucoma, Ocular Hypertension FDA OKs Vyzulta for Glaucoma, Ocular Hypertension
Latanoprostene bunod is a novel nitric-oxide-donating prostaglandin analogue that's been shown to provide consistent and sustained reduction of intraocular pressure.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Chemists have created compounds that can treat glaucoma
(RUDN University) Glaucoma is a serious disease associated with increased intraocular pressure which often leads to blindness. One of the ways to treat glaucoma is to reduce aqueous humour secretion in the ciliary body of the eye by suppressing (inhibiting) activity of special enzymes -- carbonic anhydrases. Russian scientists from RUDN University have designed new compounds that can effectively reduce intraocular pressure by isoform selective inhibiting human carbonic anhydrase. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 3, 2017 Category: International Medicine & Public Health Source Type: news

FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Nov. 2, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. (Euronext... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 2, 2017 Category: Drugs & Pharmacology Source Type: news

Second Sight wins full FDA clearance for Orion cortical prosthesis feasibility trial
Second Sight Medical (NSDQ:EYES) said today it won FDA approval to launch a feasibility clinical study of its Orion cortical visual prosthesis system. With the approval, the Sylmar, Calif.-based company is cleared to enroll up to 5 patients total at the University of California at Los Angeles and Houston’s Baylor College of Medicine. The company said it has also completed device testing and addressed outstanding questions the FDA requested upon receiving prior conditional approval in August. “We are grateful for the rapid and thorough review by the FDA and are pleased to be able to commence the Orion feasi...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Second Sight Source Type: news

Mitosol(R)'s Orphan Drug Designation is Expanded for All Glaucoma Surgery
St. Louis ophthalmic company expands designation to include all glaucoma surgery ST. LOUIS, Oct. 31, 2017 -- (Healthcare Sales & Marketing Network) -- Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has expanded its Orphan Drug Designa... Biopharmaceuticals, Ophthalmology, FDA Mobius Therapeutics, Mitosol, mitomycin, glaucoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2017 Category: Pharmaceuticals Source Type: news

Mumsnet users reveal their very unusual beauty hacks
A woman took to Mumsnet to aske for unusual beauty tips that really work, and was told to try glaucoma eye drops to thicken lashes, cider vinegar to rinse her hair and aspirin paste to kill spots. (Source: the Mail online | Health)
Source: the Mail online | Health - October 29, 2017 Category: Consumer Health News Source Type: news

Health Tip: Keep Your Eyes Healthier
-- As you grow older, your eyes are more prone to diseases such as cataracts and glaucoma. The U.S. National Institute on Aging suggests how to keep your eyes healthier: Wear sunglasses that block ultraviolet (UV) radiation, and a don a hat with a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 24, 2017 Category: General Medicine Source Type: news

'Y' a protein unicorn might matter in glaucoma
(Georgia Institute of Technology) A protein shaped like a 'Y' makes scientists do a double-take and may change the way they think about a protein sometimes implicated in glaucoma. The Y is a centerpiece in myocilin, binding four other components nicknamed propellers together like balloons on strings. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 19, 2017 Category: International Medicine & Public Health Source Type: news

FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug
The FDA advisory committee approved a new drug application for once-daily glaucoma drug netarsudil (Rhopressa), introducing a new drug class for this indication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 16, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

With nod from panel, Aerie inches toward FDA approval
Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval. On Friday, an FDA advisory committee voted in favor of Rhopressa – an Aerie eye drop product candidate for the treatment of glaucoma. The 10-pe rson panel voted unanimously that clinical trials of Rhopressa support its efficacy; it voted 9-1 that its efficacy outweighs safety risks. While the FDA normally… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 13, 2017 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

With nod from panel, Aerie inches toward FDA approval
Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval. On Friday, an FDA advisory committee voted in favor of Rhopressa – an Aerie eye drop product candidate for the treatment of glaucoma. The 10-pe rson panel voted unanimously that clinical trials of Rhopressa support its efficacy; it voted 9-1 that its efficacy outweighs safety risks. While the FDA normally… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 13, 2017 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

For Medicare Patients, Optometrists Lag in Glaucoma Testing
(MedPage Today) -- Ophthalmologist dominance a cause for professional concern? (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 13, 2017 Category: American Health Source Type: news

FDA advisory committee backs Aerie ’s Rhopressa eye drug
An FDA advisory committee voted today in favor of Aerie Pharmaceuticals‘ (NSDQ:AERI) Rhopressa product candidate. The dermatologic and ophthalmic drugs advisory committee voted unanimously that clinical trials support the efficacy of Aerie’s netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nine members of the committee voted to say that the product’s efficacy outweighs its safety risks, while one member voted against that claim. Get the full story at our sister site, Drug Delivery Business News. The post FDA advisor...
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Aerie Pharmaceuticals Source Type: news

U.S. FDA panel backs Aerie's glaucoma drug Rhopressa
(Reuters) - Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks. (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nasdaq halts trading of Aerie stock as FDA reviews Rhopressa NDA
Aerie Pharmaceuticals (NSDQ:AERI) said today that Nasdaq has halted trading of the company’s common stock as an FDA committee convenes to review Aerie’s new drug application for its Rhopressa glaucoma and ocular hypertension drug. The Irvine, Calif.-based company submitted the NDA in February and the FDA is slated to finishing reviewing the application by Feb. 28, 2018. Get the full story at our sister site, Drug Delivery Business News. The post Nasdaq halts trading of Aerie stock as FDA reviews Rhopressa NDA appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Less Macular Pigment Linked to Disability Glare in Glaucoma Less Macular Pigment Linked to Disability Glare in Glaucoma
Lower macular pigment optical density (MPOD) is associated with glare-associated visual function and central visual field loss in patients with open-angle glaucoma, researchers report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 13, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Sight Sciences raises $10m in Series C
Ophthalmic medical device company Sight Sciences said this week it closed a $10 million oversubscribed Series C round to support expanding manufacturing and its US commercial team and the launch of its devices into the dry eye and microinvasive surgery markets. The round was led by Allegro Investment Fund and was joined with full participation from existing Series A and Series B investors, the Menlo Park, Calif.-based company said. As part of the funding around, Allegro’s chairman Steffan Encrantz will join the company’s board of directors as chair. Funds are also slated to support expanding the compa...
Source: Mass Device - October 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Sight Sciences Source Type: news

Aerie's glaucoma drug effectively lowers eye pressure: FDA review
(Reuters) - Aerie Pharmaceuticals Inc's experimental glaucoma treatment Rhopressa is effective in lowering eye pressure, a preliminary review by the U.S. Food and Drug Administration concluded. (Source: Reuters: Health)
Source: Reuters: Health - October 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

University of Iowa researchers use CRISPR engineering to prevent certain glaucoma in mice
(University of Iowa Health Care) A University of Iowa-led team of researchers has used the gene editing method called CRISPR-Cas9 to disrupt a mutant gene that is responsible for some forms of glaucoma, one of the most common causes of irreversible blindness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 2, 2017 Category: International Medicine & Public Health Source Type: news

Medical News Today: Natural protein may help to prevent blindness
Researchers have shed light on the mechanisms underlying glaucoma, a leading cause of blindness, which could lead to new treatments for the disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2017 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Nigeria: The Silent Thief of Sight - Early Detection Can Prevent Blindness From Glaucoma
[Nigeria Health Watch] Editor's Note: Glaucoma is the leading cause of irreversible blindness in the world, with the highest number affected in Sub-Saharan Africa. This week (March 12 - 18, 2017) is World Glaucoma Week, and this year's theme is BIG; Beat Invisible Glaucoma. Our Thought Leadership Series Piece this week is by Consultant Opthamologist Fatima Kyari. She explains the danger of the silent and gradual blindness caused by glaucoma, and lays out ways in which we can all help improve awareness and services for glaucoma p (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 29, 2017 Category: African Health Source Type: news

Can You Cure Glaucoma?
Title: Can You Cure Glaucoma?Category: Doctor's& Expert's views on SymptomsCreated: 9/27/2017 12:00:00 AMLast Editorial Review: 9/27/2017 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 27, 2017 Category: Opthalmology Source Type: news

Forsight Vision6 drums up another $3m
The sixth company to come out ophthalmology incubator ForSight Labs said today that it raised $3.0 million from a syndicate of nine unnamed investors. Stealthy ForSight Vision6 revealed the equity round in a regulatory filing today. The company added $3.0 million in December 2014 to the $1 million is raised in 20153 from a lone backer. Forsight Labs has a record of successful spinouts. In YYadte Allergan (NYSE: AGN) agreed to pay $95 million for ForSight Vision5 and its Helios drug-eluting ophthalmological implant, with a possible milestone payment for launching its drug-eluting device. The He...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Optical/Ophthalmic Wall Street Beat ForSight Vision Source Type: news

Coming Soon: Glaucoma Self-Care, From Home?
Study finds many patients can manage self-testing, but one doctor questions its value (Source: WebMD Health)
Source: WebMD Health - September 22, 2017 Category: Consumer Health News Source Type: news

Coming Soon: Glaucoma Self-Care, from Home?
Study finds many patients can manage self-testing, but one doctor questions its value Source: HealthDay Related MedlinePlus Pages: Glaucoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 22, 2017 Category: Consumer Health News Source Type: news

Coming Soon: Glaucoma Self-Care, From Home?
FRIDAY, Sept. 22, 2017 -- For many glaucoma patients, repeat trips to a doctor's office to check on their eyes can be a real pain. But new research supports the usefulness of a device that allows glaucoma patients to measure their own eye pressure... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 22, 2017 Category: General Medicine Source Type: news

Coming Soon: Glaucoma Self-Care, From Home?
Title: Coming Soon: Glaucoma Self-Care, From Home?Category: Health NewsCreated: 9/22/2017 12:00:00 AMLast Editorial Review: 9/22/2017 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 22, 2017 Category: Opthalmology Source Type: news

How Well Can Glaucoma Patients Measure Their Own Intraocular Pressure? How Well Can Glaucoma Patients Measure Their Own Intraocular Pressure?
Self-measurement of intraocular pressure (IOP) by glaucoma patients is feasible and acceptable, but it remains to be seen whether it is sufficiently accurate to guide clinical management, according to an observational study.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 7, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Aerie launches Ph3 trial for Roclatan eye drug in Europe
Aerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension. The eye drug is a fixed dose combination of Aerie’s Rhopressa netarsudil ophthalmic solution and a widely-used prostaglandin analogue, latanoprost. The company’s Phase III trial was designed to support regulatory approval and commercialization in Europe, Aerie said. Get the full story at our sister site, Drug Delivery Business News. The post Aerie launches Ph3 trial for Roclatan eye drug in Europe appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Risk Factors for Rapid Glaucoma: Ophthalmology Times
(MedPage Today) -- Also, first-hand experience with extended depth of focus intraocular lenses (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 6, 2017 Category: American Health Source Type: news

FDA clears Second Sight IDE trial of next-gen Orion cortical visual prosthesis
Second Sight Medical (NSDQ:EYES) said today it won FDA investigational device exemption to initiate a feasibility clinical study of its Orion cortical visual prosthesis system. The conditional approval gives the Sylmar, Calif.-based company clearance to enroll up to 5 patients at 2 US sites, but requires that the company conduct additional device testing and “address outstanding questions” within 45 days, it said. “This is an exciting milestone for the company given the potential of Orion to provide useful vision to millions of blind individuals worldwide who have no other option today. We are deligh...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Prosthetics second-sight-medical Source Type: news

Efficacy of Gel Microstent for Primary Open-Angle Glaucoma Efficacy of Gel Microstent for Primary Open-Angle Glaucoma
Where does the gel microstent XEN ® fall among emerging devices and procedures for IOP reduction in primary open-angle glaucoma?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2017 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Valeant ’s Tampa manufacturing plant on track for a better bill of health
The giant pharmaceutical company that owns a Tampa manufacturing plant that makes Bausch& Lomb products says it ’s on track to fix the problems at the facility that kept it from winning approval for a new glaucoma drug. The U.S. Food and Drug Administration has confirmed that issues related to a Good Manufacturing Practice inspection at the plant are being resolved, Joseph Papa, chairman and CEO of Valeant Pharmaceutical International Inc. (NYSE: VRX) said Wednesday. Valeant, based in Laval,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 17, 2017 Category: Health Management Authors: Margie Manning Source Type: news

Allergan gel-based stents are treating glaucoma
[Image from University of Michigan]An Allergan-developed gelatin-based stent is showing potential to treat glaucoma in a quicker and safer environment, according to new research from the University of Michigan. Glaucoma is a disease that damages the eye’s optic nerve and can cause vision loss and blindness. Medicines in the form of eyedrops or pills can be used to treat glaucoma. Another option is laser trabeculoplasty which helps drain fluid from the eye. Conventional surgery also creates a new opening in the eye for fluid to leave. Both surgical options are invasive and prone to complications. With the amount of gl...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Stents Surgical Allergan Inc. Glaucoma MedTech Source Type: news